Skip to main content

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with newly launched Elevation Oncology to accelerate patient identification and enrollment for Elevation Oncology’s Phase 2 CRESTONE study evaluating the use of seribantumab in patients with recurrent, locally advanced or metastatic solid tumors of any origin that have a neuregulin-1 (NRG1) gene fusion.

Read Article